Despite the use of current first-line treatment i.e., the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for diffuse large B-cell lymphoma (DLBCL), the rates of relapse remain high.1 Eventually, there came a breakthrough on April 19, 2023, when the Unit

Since the introduction of anthracyclines, they have been associated with cumulative and dose-dependent cardiotoxicity.¹ The updated European Society of Cardiology (ESC) guidelines endorse echocardiography (ECG) assessments at baseline and 12 months of treatment, with further surveillance if the cumulative dose reaches an equivalence of doxorubicin 250mg/m².² Of note, previous studies reported a cumulative decrease in left ventricular ejection fraction (LVEF).¹ However, in a recent retrospective case-controlled report, there was no significant difference in the chronic heart failure (CHF) risk based on cumulative anthracycline dose, and that among cancer patients who were not treated with anthracyclines, the risk of CHF was also not statistically significant compared with healthy controls.²

Most of the Hodgkin lymphoma (HL) patients respond well to frontline treatment, but such treatments induce unacceptable organ toxicities and immune suppression, which leads to secondary malignancies and cardiac disease.¹ Therefore, increased interest has drawn towards targeted